Key Takeaways SRPT is pausing U.S. Elevidys shipments to complete safety labeling changes and respond to FDA requests. The move follows patient deaths linked to ALF in studies using the same AAVrh74 gene therapy vector. SRPT expects significant financial impact in quarters ahead as Elevidys drove over half of its Q1 revenues.Shares of Sarepta Therapeutics (SRPT) are declining in the pre-market hours today after the announcement that it will voluntarily and temporarily halt all U.S. shipments of Elevidys, ...

Key Takeaways SRPT shares fell 35.9% after a third death in its muscular dystrophy gene therapy program from liver failure. FDA placed LGMD studies on hold and urged a halt to Elevidys shipments; SRPT refused, citing safety data. Sarepta will cut 36% of staff and focus on siRNA assets to save $400M annually and stabilize operations.Shares of Sarepta Therapeutics (SRPT) nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies.The company confirmed that a ...